--- title: "Weekly Recap | GENSCRIPT BIO -8.92%, pullback outpacing the Hang Seng Index" type: "News" locale: "en" url: "https://longbridge.com/en/news/306350375.md" description: "GenScript Biotech (1548.HK) fell 8.92% this week to close at HK$27.76, underperforming the Hang Seng Index’s 5.65% decline by about 3.27 percentage points. The stock swung between HK$28.36 and HK$31.60 from Monday to Wednesday, then dropped sharply on Thursday to HK$27.32 before settling at HK$27.76. No major catalyst emerged this week." datetime: "2026-11-21T05:13:13.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/306350375.md) - [en](https://longbridge.com/en/news/306350375.md) - [zh-HK](https://longbridge.com/zh-HK/news/306350375.md) generator: "portal-rs" --- # Weekly Recap | GENSCRIPT BIO -8.92%, pullback outpacing the Hang Seng Index ## The Week GenScript Biotech (1548.HK) fell 8.92% this week to close at HK$27.76, underperforming the Hang Seng Index’s 5.65% decline by about 3.27 percentage points. The stock swung between HK$28.36 and HK$31.60 from Monday to Wednesday, then dropped sharply on Thursday to HK$27.32 before settling at HK$27.76. No major catalyst emerged this week. ## Analyst Ratings Seven brokers cover the stock: five rate it buy and two rate it overweight, with no hold or sell ratings. The consensus rating is strong buy, with a consensus target price of HK$45.44, roughly 63.7% above the latest close. Targets range from HK$29.999 to HK$87.98, showing wide dispersion. The stock ranks 8th out of 12 names in the life sciences tools and services industry. ## The Week Ahead GenScript Biotech is set to report fiscal Q3 2026 results after market close on Monday, 23 November 2026. The full-year 2026 annual results are due on 15 March 2027, with consensus estimates at HK$0.0502 EPS and HK$7.047 billion in revenue. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [01548.HK](https://longbridge.com/en/quote/01548.HK.md) ## Related News & Research - [AIâs billions and slick pledges heap pressure on pharma veterans](https://longbridge.com/en/news/306270834.md) - [M Stanley: China AI Drug R&D Financing Accelerates, GENSCRIPT BIO Benefits from Wet Lab Demand](https://longbridge.com/en/news/304828812.md) - [GENSCRIPT BIO Picks Up 5% after Lower Open](https://longbridge.com/en/news/296046962.md) - [Public Power Corporation S.A. Just Missed Revenue By 7.1%: Here's What Analysts Think Will Happen Next](https://longbridge.com/en/news/306350012.md) - [Huatai Raises GENSCRIPT B-1K Earnings Forecasts on AIDD Benefits, Reiterates Buy](https://longbridge.com/en/news/304381452.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**